Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. was established in April 2009. It is a high-tech biomedical enterprise focusing on the research, development and production of peptide drugs and chemical drugs.The company is located in Jiangyin High-tech Development Zone, Jiangsu Province, and is a national high-tech enterprise.There are wholly-owned R&D subsidiaries Changchun ProteLight Pharmaceutical & Biotechnology Co., Ltd. and Nanjing Denovo Pharmaceutical Technology Co., Ltd., as well as subsidiaries Jiangsu Putai Pharmaceutical Technology Co., Ltd. and ProteLight Medical Holdings (Hong Kong) Co., Ltd.
The company takes the development and production of innovative drugs as its core development strategy and has formed a variety of new peptide drug R&D pipelines led by first-in-class anti-infective drugs and anti-cancer drugs. The company currently has a number of national first-in-class innovative drug research projects and has dozens of patents, including PCT international invention patents, US and EU invention patents, Chinese invention patents, utility model, and appearance patents.
Since its establishment, the company has undertaken more than 40 science and technology research projects, including the National Health Commission’s 12th and 13th Five-Year "Major New Drug Creation" science and technology projects, and the Ministry of Human Resources and Social Security "Selected funding for scientific and technological innovation and entrepreneurship projects for overseas students".
In the future, based on the antimicrobial peptide series products, the company will maintain the advantages of equal emphasis on R&D and production, expand the market with high-quality innovative products, and strive to become the leader of international antimicrobial peptide pharmaceutical enterprises!